Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silence Therapeutics Plc ADR (NQ: SLN )

18.25 +0.82 (+4.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 301,753
Open 17.54
Bid (Size) 18.02 (1)
Ask (Size) 18.98 (2)
Prev. Close 17.43
Today's Range 17.36 - 18.36
52wk Range 6.150 - 27.72
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
From Silence Therapeutics plc
Via Business Wire
Analyst Expectations For Silence Therapeutics's Future
Via Benzinga

Performance

YTD
-1.62%
-1.62%
1 Month
-3.95%
-3.95%
3 Month
-3.95%
-3.95%
6 Month
-15.51%
-15.51%
1 Year
+88.14%
+88.14%

More News

Read More
SLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024
Via InvestorPlace
Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
The 3 Best Gene Editing Stocks to Buy in August 2024
Via InvestorPlace
The Analyst Landscape: 6 Takes On Silence Therapeutics
Via Benzinga
What 7 Analyst Ratings Have To Say About Silence Therapeutics
Via Benzinga
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
Via Benzinga
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
Via InvestorPlace
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
From Silence Therapeutics plc
Via Business Wire
What 4 Analyst Ratings Have To Say About Silence Therapeutics
Via Benzinga
Silence Therapeutics to Present at Jefferies Global Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
SLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024
Via InvestorPlace
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
From Silence Therapeutics plc
Via Business Wire
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Via InvestorPlace
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
From Silence Therapeutics plc
Via Business Wire
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
Via InvestorPlace
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
Via Benzinga
What's Going On With Silence Therapeutics Stock Today?
Via Benzinga
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
From Silence Therapeutics plc
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.